Sage Therapeutics, Inc. Investors: Important Class Action Update

Author: Owen Jenkins Updated: 09-18-2024 01:48 PM

Important Update for Sage Therapeutics, Inc. Shareholders

The Gross Law Firm has issued a significant notice concerning shareholders of Sage Therapeutics, Inc. (SAGE). Investors who acquired shares during the class period should take note of this development. This class action could provide a path for recovery for affected shareholders.

Eligibility for Lead Plaintiff Appointment

If you are a shareholder who purchased shares of SAGE during the specified class period, you are encouraged to reach out to the firm about the possibility of being appointed as a lead plaintiff. It's essential to understand that there is no obligation to become a lead plaintiff to participate in any recovery.

Details of the Class Period

The class period for this action spans from April 12, 2021, to July 23, 2024. Shareholders within this timeframe may have claims arising from misleading statements made by the company.

Allegations Against Sage Therapeutics, Inc.

The lawsuit revolves around allegations that the company made materially false or misleading statements regarding its drug Zuranolone, particularly concerning its efficacy in treating Major Depressive Disorder (MDD). It is believed that the company overstated both the drug's potential and its likelihood of regulatory approval by the FDA.

Specific Claims

The key allegations include the following:
(i) Zuranolone was thought to be less effective for MDD than communicated, which raises questions about its future approval prospects.
(ii) Concerns regarding the efficacy of SAGE-718 in treating Mild Cognitive Impairment due to Parkinson's Disease.
(iii) Similar concerns regarding SAGE-324 and its effectiveness in treating essential tremors.

Next Steps for Shareholders

For shareholders wishing to register in the class action, timely registration is crucial. The final deadline for registering is approaching on October 28, 2024. Once registered, shareholders will have access to a monitoring service, providing updates on the case’s progress throughout its duration.

Why Choose the Gross Law Firm?

The Gross Law Firm stands out as a nationally recognized entity that prioritizes the protection of investor rights. Its commitment lies in pursuing justice for those who have experienced losses due to potential fraud and misleading practices by companies. The firm emphasizes promoting ethical business conduct and accountability.

Contact Information for Inquiries

For further information or inquiries, shareholders can directly contact the Gross Law Firm:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903

Frequently Asked Questions

What should I do if I purchased SAGE shares during the class period?

If you purchased SAGE shares during the class period, consider reaching out to the Gross Law Firm to discuss the possibility of participating in the class action.

What is the class period for the securities action?

The class period for this action is from April 12, 2021, to July 23, 2024.

What allegations are made against Sage Therapeutics?

The allegations include false statements regarding the effectiveness of its drugs and their prospects for FDA approval.

How can I register for the class action?

Shareholders can register by contacting the Gross Law Firm and providing required information about their share purchases.

What benefits do I get from registering?

Registering allows you to monitor the case and receive updates, as well as potentially recover losses incurred.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.